[go: up one dir, main page]

AR043832A1 - Compuestos de carbonilo y proceso de preparacion de los mismos - Google Patents

Compuestos de carbonilo y proceso de preparacion de los mismos

Info

Publication number
AR043832A1
AR043832A1 ARP040101114A ARP040101114A AR043832A1 AR 043832 A1 AR043832 A1 AR 043832A1 AR P040101114 A ARP040101114 A AR P040101114A AR P040101114 A ARP040101114 A AR P040101114A AR 043832 A1 AR043832 A1 AR 043832A1
Authority
AR
Argentina
Prior art keywords
atoms
hal
coor3
het
monosubstituted
Prior art date
Application number
ARP040101114A
Other languages
English (en)
Inventor
Tsaklakidis Christos Dr
Dipl Chem Dorsch Dieter Dr
Mederski Werner Dr
Cezanne Bertram Dr
Gleitz Johannes Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33135449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR043832(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10315377A external-priority patent/DE10315377A1/de
Priority claimed from DE2003129295 external-priority patent/DE10329295A1/de
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR043832A1 publication Critical patent/AR043832A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Los compuestos de la fórmula (1) en donde R1 y R2 son cada uno, de modo independiente entre si, H, =O, Hal, A, etinilo, OR3, N(R3)2, NO2, CN, N3, COOR3, CON(R3)2, -[C(R4)2]n-Ar, -[C(R4)2]n-Het, -[C(R4)2]n-cicloalquilo, -OCOR3, -OCON(R3)2, NR3COA o NR3SO2A; R1 y R2 son juntos, de modo alternativo, un anillo carbocíclico o heterocíclico de 3 a 7 miembros unido de forma bicíclica o espirocíclica que tiene de 0 a 3 átomos de N, O y/o S, R3 es H, A. H-C:::C-CH2-, -CH3-C:::C-CH2-, -CH2-CH(OH)-CH2OH, -CH2-CH(OH)-CH2NH2, -CH2-CH(OH)-CH2Het´, -[C(R4)2]n-Ar´, -[C(R4)2]n-Het´, -[C(R4)2]n-cicloalquilo, -[C(R4)2]n-COOA o, -[C(R4)2]n-N(R4)2; R4 es H o A; W es N, CR3 o un átomo de C hibridado en sp2; E es, junto con W un anillo carbocíclico o heterocíclico saturado de 3 a 7 miembros que tiene de 0 a 3 átomos de N, de 0 a 2 átomos de O y/o de 0 a 2 átomos de S; el cual puede contener un doble enlace, D es un anillo carbocíclico o heterocíclico monocíclico o bicíclico aromático que tiene de 0 a 4 átomos de N, O y/o S que está insustituido o monosustituido o polisustituido con Hal, A, OR3, N(R3)2, NO2, CN, COOR3 o CON(R3)2; G es -[C(R4)2]n-, -[C(R4)2]n-NR3-, -[C(R4)2]n-O-, -[C(R4)2]n-S- o [C(R4)=C(R4)]n-, X es -[C(R4)2]n-CONR3-[C(R4)2]n-, -[C(R4)2]n-NR3CO[C(R4)2]n-, -[C(R4)2]n-NR3[C(R4)2]n-, -[C(R4)2]n-O [C(R4)2]n-,-[C(R4)2]n CO [C(R4)2]n-, o [C(R4)2]nCOO [C(R4)2]n-, Y es alquileno, cicloalquileno, Het-diilo o Ar-diilo, T es un anillo carbocíclico o heterocíclico monocíclico o bicíclico, saturado o insaturado que tiene de 0 a 4 átomos de N, O y/o S que está monosustituido o disustituido con =O, =S, =NR3, =N-CN, =N-NO2, =NOR3, =NCOR3, =NCOOR3 o =NOCOR3 y además puede estar monosustituido, disustituido o trisustituido con R3, Hal, A, -[C(R4)2]n-Ar, -[C(R4)2]n-Het, -[C(R4)2]n-cicloalquilo, OR3, N(R3)2, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3CON(R3)2, NR3SO2A, COR3, SO2NR3 y/o S(O)nA; A es alquilo lineal o ramificado que tiene 1-10 átomos de C, en el cual uno o dos grupos CH2 pueden estar reemplazados por átomos de O o S y/o por grupos -CH=CH- y/o además, 1-7 átomos de H pueden estar reemplazados por F; Ar es fenilo, naftilo o bifenilo, cada uno de los cuales está insustituido o monosustituido, disustituido o trisustituido con Hal, A, OR3, N(R3)2, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3CON(R3)2, NR3SO2A, COR3, SO2N(R3)2, S(O)nA; -[C(R4)2]n-COOR3 u -O[C(R4)2]o-COOR3, Ar´ es fenilo, naftilo o bifenilo, cada uno de los cuales está insustituido o monosustituido, disustituido o trisustituido con Hal, A, OR4, N(R4)2, NO2, CN, COOR4, CON(R4)2, NR4COA, NR4CON(R4)2, NR4SO2A, COR4, SO2N(R4)2, S(O)nA; -[C(R4)2]n-COOR4 u -O[C(R4)2]o-COOR4; Het es un anillo heterocíclico monocíclico o bicíclico, saturado, insaturado o aromático que tiene de 1 a 4 átomos de N, O y/o S que puede estar insustituido o monosustituido, disustituido o trisustituido con Hal, A, -[C(R4)2]n-Ar, -[C(R4)2]n-Het´, -[C(R4)2]n-cicloalquilo, OR3, N(R3)2, NR3CON(R3)2, NO2, CN, -[C(R4)2]n-COOR3, -[C(R4)2]n-CON(R3)2, NR3COA, NR3SO2A, COR3, SO2NR3, S(O)mA y/u O del carbonilo; Het´ es un anillo heterocíclico monocíclico o bicíclico, saturado, insaturado o aromático que tiene de 1 a 4 átomos de N, O y/o S que puede estar insustituido o monosustituido o disustituido con el O del carbonilo, =S., =N(R4)2, Hal, A, OR4, N(R4)2, NO2, CN, COOR4, CON(R4)2, NR4COA, NR4CON(R4)2, NR4SO2A, COR4, SO2NR4 y/o S(O)nA, Hal es F, Cl, Br o I, n es 0, 1 o 2; o es 1, 2 o 3; y sus derivados, solvatos, sales y estereoisómeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones. Son inhibidores del factor de coagulación Xa y pueden emplearse para la profilaxis y/o la terapia de enfermedades tromboembólicas y para el tratamiento de tumores.
ARP040101114A 2003-04-03 2004-04-02 Compuestos de carbonilo y proceso de preparacion de los mismos AR043832A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10315377A DE10315377A1 (de) 2003-04-03 2003-04-03 Carbonylverbindungen
DE2003129295 DE10329295A1 (de) 2003-06-30 2003-06-30 Carbonylverbindungen
US48389703P 2003-07-02 2003-07-02

Publications (1)

Publication Number Publication Date
AR043832A1 true AR043832A1 (es) 2005-08-17

Family

ID=33135449

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101114A AR043832A1 (es) 2003-04-03 2004-04-02 Compuestos de carbonilo y proceso de preparacion de los mismos

Country Status (22)

Country Link
US (2) US7906516B2 (es)
EP (1) EP1720844B1 (es)
JP (1) JP4705015B2 (es)
KR (1) KR20050118708A (es)
AR (1) AR043832A1 (es)
AT (1) ATE430139T1 (es)
AU (1) AU2004226278B2 (es)
BR (1) BRPI0408420A (es)
CA (1) CA2521069C (es)
CL (1) CL2004000720A1 (es)
CO (1) CO5660267A2 (es)
DE (1) DE502004009440D1 (es)
EC (1) ECSP056131A (es)
ES (1) ES2325077T3 (es)
IL (1) IL171214A (es)
MX (1) MXPA05010444A (es)
MY (1) MY140031A (es)
NZ (1) NZ543366A (es)
PE (1) PE20050015A1 (es)
PL (1) PL377633A1 (es)
TW (1) TW200512200A (es)
WO (1) WO2004087646A2 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10358814A1 (de) 2003-12-16 2005-07-21 Merck Patent Gmbh Prolinylarylacetamide
CA2550012A1 (en) * 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same and use
WO2006022442A1 (ja) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
DE102004045796A1 (de) * 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
DE102004047254A1 (de) * 2004-09-29 2006-04-13 Merck Patent Gmbh Carbonylverbindungen
WO2006100565A1 (en) * 2005-03-24 2006-09-28 Warner-Lambert Company Llc Crystalline forms of a known pyrrolidine factor xa inhibitor
US7820699B2 (en) * 2005-04-27 2010-10-26 Hoffmann-La Roche Inc. Cyclic amines
KR20080067697A (ko) * 2005-11-11 2008-07-21 에프. 호프만-라 로슈 아게 응고 인자 ｘａ의 억제제로서 카보사이클릭 융합된사이클릭 아민
US7601752B2 (en) * 2005-11-16 2009-10-13 Hoffmann-La Roche Inc. Pyrrolidine derivatives
CA2634743C (en) 2005-12-23 2014-07-29 Zealand Pharma A/S Modified lysine-mimetic compounds
EP2007377A4 (en) * 2006-04-06 2011-08-17 Glaxo Group Ltd ANTIBACTERIAL ACTIVE SUBSTANCES
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
EP2007756B1 (en) 2006-04-07 2015-08-26 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
AU2007251614B2 (en) * 2006-05-16 2013-01-17 Boehringer Ingelheim International Gmbh Substituted prolinamides, production thereof and their use as drugs
ATE493984T1 (de) 2006-10-18 2011-01-15 Pfizer Prod Inc Biaryl-ether-harnstoffverbindungen
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
PL2468724T3 (pl) 2006-12-21 2016-05-31 Zealand Pharma As Synteza związków pirolidynowych
TW200911787A (en) * 2007-07-03 2009-03-16 Astrazeneca Ab New aza-bicyclohexane compounds useful as inhibitors of thrombin
DE102008020053A1 (de) * 2008-04-22 2009-10-29 Merck Patent Gmbh Feste pharmazeutische Zubereitung enthaltend 1-[(4-chloro-phenyl)-amid]-2-{[4-(3-oxo-morpholin-4-yl)-phenyl]-amid}-4-hydroxy-pyrrolidin-1,2-dicarbonsäure
CA2721815C (en) 2008-05-07 2014-06-10 Yasunori Tsuzuki Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same
US8673920B2 (en) * 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2011025565A1 (en) * 2009-08-31 2011-03-03 Mochida Pharmaceutical Co., Ltd. Morpholinone compounds as factor ixa inhibitors
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP3381899B1 (en) 2010-04-22 2021-01-06 Vertex Pharmaceuticals Incorporated Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds
US9073882B2 (en) 2010-10-27 2015-07-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9056859B2 (en) 2010-10-29 2015-06-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CN103402996B (zh) 2011-01-04 2015-02-11 诺瓦提斯公司 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
RU2014110401A (ru) 2011-08-19 2015-09-27 Мерк Шарп И Доум Корп. Ингибиторы внешнего медуллярного калиевого канала почек
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9527830B2 (en) 2011-09-16 2016-12-27 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2771005B1 (en) 2011-10-25 2016-05-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013062900A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773206B1 (en) 2011-10-31 2018-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9493474B2 (en) 2011-10-31 2016-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9139585B2 (en) 2011-10-31 2015-09-22 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
EP2790511B1 (en) 2011-12-16 2016-09-14 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JO3398B1 (ar) 2011-12-22 2019-10-20 Novartis Ag مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
JP2015083542A (ja) * 2012-02-08 2015-04-30 大日本住友製薬株式会社 ３位置換プロリン誘導体
WO2014002053A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
CN104640855B (zh) 2012-06-28 2017-08-29 诺华股份有限公司 补体途经调节剂及其用途
US9464081B2 (en) 2012-06-28 2016-10-11 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
EP2867225B1 (en) 2012-06-28 2017-08-09 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
ES2710491T3 (es) 2012-06-28 2019-04-25 Novartis Ag Moduladores de la vía del complemento y sus usos
CN104684910B (zh) 2012-07-12 2016-10-12 诺华股份有限公司 补体途经调节剂及其用途
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
JP6220786B2 (ja) * 2012-07-19 2017-10-25 大日本住友製薬株式会社 １−（シクロアルキルカルボニル）プロリン誘導体
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
EP2925322B1 (en) 2012-11-29 2018-10-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9573961B2 (en) 2012-12-19 2017-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014126944A2 (en) 2013-02-18 2014-08-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US9765074B2 (en) 2013-03-15 2017-09-19 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP3027625B1 (en) 2013-07-31 2018-05-30 Merck Sharp & Dohme Corp. Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure
WO2015065866A1 (en) 2013-10-31 2015-05-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP3095786A4 (en) * 2014-01-14 2017-10-11 Sumitomo Dainippon Pharma Co., Ltd. Condensed 5-oxazolidinone derivative
JP6543268B2 (ja) 2014-04-15 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
PL4019022T3 (pl) 2015-10-01 2024-06-24 Biocryst Pharmaceuticals, Inc. Inhibitory ludzkiej kalikreiny osoczowej
JP6930972B2 (ja) 2015-12-02 2021-09-01 シンジェンタ パーティシペーションズ アーゲー 殺微生物性オキサジアゾール誘導体
US20190119642A1 (en) 2016-03-15 2019-04-25 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
EP3618847B1 (en) 2017-05-05 2021-04-07 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
WO2018219773A1 (en) 2017-06-02 2018-12-06 Syngenta Participations Ag Fungicidal compositions
US11447481B2 (en) 2017-06-02 2022-09-20 Syngenta Participations Ag Microbiocidal oxadiazole derivatives

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1076114A (en) * 1975-02-10 1980-04-22 Mitsubishi Chemical Industries Limited 1,5-alkylene-3-aryl hydantoin derivatives
US5705487A (en) 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
IL112795A (en) 1994-03-04 2001-01-28 Astrazeneca Ab Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them
US5691356A (en) * 1994-03-21 1997-11-25 Bristol-Myers Squibb Company Disubstituted heterocyclic thrombin inhibitors
EP1140903B1 (en) 1998-12-23 2004-08-04 Eli Lilly And Company Aromatic amides
US6673817B1 (en) 1999-05-24 2004-01-06 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
AU5284000A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
ATE308540T1 (de) 2000-08-17 2005-11-15 Lilly Co Eli Antithrombosemittel
DE60122750T2 (de) 2000-09-11 2006-12-21 Genentech, Inc., South San Francisco Amidin-Inhibitoren von Serin-Proteasen
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
DE10102322A1 (de) 2001-01-19 2002-07-25 Merck Patent Gmbh Phenylderivate
DE10113402A1 (de) 2001-03-20 2002-09-26 Merck Patent Gmbh Biurethanderivate
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
PL208928B1 (pl) * 2001-04-16 2011-06-30 Pharmacopeia 3, 4-di-podstawione cyklobuten-1, 2-diony jako ligandy receptora CXC chemokiny
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
WO2003050088A1 (en) * 2001-12-07 2003-06-19 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity

Also Published As

Publication number Publication date
US20060183739A1 (en) 2006-08-17
ES2325077T3 (es) 2009-08-25
JP4705015B2 (ja) 2011-06-22
DE502004009440D1 (de) 2009-06-10
WO2004087646A2 (de) 2004-10-14
CA2521069A1 (en) 2004-10-14
US8129373B2 (en) 2012-03-06
EP1720844A2 (de) 2006-11-15
US7906516B2 (en) 2011-03-15
TW200512200A (en) 2005-04-01
US20100256131A1 (en) 2010-10-07
BRPI0408420A (pt) 2006-03-21
WO2004087646A3 (de) 2005-01-06
NZ543366A (en) 2008-11-28
ECSP056131A (es) 2006-03-01
IL171214A (en) 2011-03-31
AU2004226278B2 (en) 2010-07-29
JP2006522033A (ja) 2006-09-28
CO5660267A2 (es) 2006-07-31
PL377633A1 (pl) 2006-02-06
EP1720844B1 (de) 2009-04-29
MXPA05010444A (es) 2005-11-04
ATE430139T1 (de) 2009-05-15
CL2004000720A1 (es) 2005-01-14
KR20050118708A (ko) 2005-12-19
PE20050015A1 (es) 2005-02-18
AU2004226278A1 (en) 2004-10-14
MY140031A (en) 2009-11-30
CA2521069C (en) 2012-09-18

Similar Documents

Publication Publication Date Title
AR043832A1 (es) Compuestos de carbonilo y proceso de preparacion de los mismos
AR050945A1 (es) Medicamentos que contienen compuestos de carbonilo y su uso
AR041024A1 (es) Derivados de benzimidazol como inhibidores del factor de coagulacion xa
Figge et al. Cancer detection and therapy. Affinity of neoplastic, embryonic, and traumatized tissues for porphyrins and metalloporphyrins.
BR0308816A (pt) Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas
AR050155A1 (es) 3-aminoindazoles, un procedimiento de preparcion, uso de los compuestos para preparar medicamentos, dichos medicamentos y un compuesto intermediario
AR049502A1 (es) Derivados de carbonilo heterociclicos
AR034870A1 (es) Derivados de 8-metoxi-[1,2,4]triazolo[1,5-a]piridina
NL300070I1 (nl) Eletriptanum, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder het hydrobormide.
AR072792A1 (es) DERIVADOS DE PIRROLOPIRIDINILPIRIMIDIN-2-IL-AMINA, PROCEDIMIENTO DE PREPARACIoN Y COMPOSICIONES FARMACEUTICAS
BR0116115A (pt) Derivados de carboxamida e seu uso no tratamento de doenças tromboembólicas e tumores
BR112022016131A2 (pt) Compostos para tratamento de infecção por coronavírus
AR045040A1 (es) Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos
KR890012970A (ko) 테트라히드로 이소퀴놀린 유도체
CO2025007341A2 (es) Inhibidor del inflamosoma nlrp3 y uso de este
AR061810A1 (es) Derivados de sulfamato de benzotiofeno, medicamentos que los contienen, usos para prevenir o tratar enfermedades dependientes de estrogenos y metodo de preparacion
AR042115A1 (es) Amidas de acido carboxilico
TR200401716T4 (tr) Yeni üç yerdeğiştirme gruplu fenil türevleri ve analogları
KR890008123A (ko) 디-3급-부틸페놀 화합물의 사이클릭 유도체
UY28787A1 (es) Derivados de beta-aminoacidos como inhibidores del factor xa
BR9916669A (pt) Uso de derivados de ácidos 4-biarilbutìricos e 5-biarilpentanóicos substituìdos como inibidores de metaloproteases de matriz para o tratamento de doenças respiratórias
RU2009114731A (ru) Производное пиразолопиримидина
BR0318533A (pt) azolidinacarbonitrilas e seu uso como inibidores de dpp-iv
AR037342A1 (es) Sulfonamidas ciclicas, inhibidores del factor xa de la coagulacion
AR043108A1 (es) Derivados de amida de acido carboxilico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal